Clinical nutrition最新文献

{"title":"Associations between sarcopenic, obesity, and sarcopenic obesity and metabolic syndrome in adults aged 45 Years or older: A prospective cohort study from the China health and retirement longitudinal study","authors":"Yongai Li ,&nbsp;Yingqi Wang ,&nbsp;Jianxuan Gao ,&nbsp;Tong Meng ,&nbsp;Huabin Yin","doi":"10.1016/j.clnu.2025.04.003","DOIUrl":"10.1016/j.clnu.2025.04.003","url":null,"abstract":"<div><h3>Background</h3><div>Although previous studies have reported associations between sarcopenic obesity (SO) and metabolic syndrome (MetS), the findings remain inconsistent. This study aimed to investigate the associations between sarcopenia, obesity, and MetS, and to determine whether sarcopenic obesity synergistically increases the risk of MetS.</div></div><div><h3>Methods</h3><div>The data were extracted from the China Health and Retirement Longitudinal Study (CHARLS) in 2011 and 2015. Participants were categorized into five groups: non-sarcopenia non-obesity, non-sarcopenia obesity, non-obesity sarcopenia, possible SO, and SO. MetS was defined using the diagnostic criteria recommended by the National Cholesterol Education Program Adult Treatment Panel III. Logistic regression models were employed for both cross-sectional and longitudinal analysis.</div></div><div><h3>Results</h3><div>In 2011, a total of 9322 participants were included in the cross-sectional analysis, with 3674 individuals followed up in 2015. In the cross-sectional study, non-sarcopenia obesity (OR = 9.20, CI: 8.06 to 10.50), possible SO (OR = 2.04, CI: 1.94 to 2.15), and SO (OR = 1.61, CI: 1.47 to 1.77) were associated with a higher prevalence of MetS. In contrast, non-obesity sarcopenia (OR = 0.85, CI: 0.74 to 0.98) was associated with a lower prevalence. In the longitudinal analysis, non-sarcopenia obesity (OR = 2.87, CI: 2.34 to 3.52) and possible SO (OR = 1.41, CI: 1.30 to 1.53) were associated with an increased incidence of MetS, while non-obesity sarcopenia (OR = 0.75, CI: 0.62 to 0.91) was associated with a reduced incidence. Notably, SO (OR = 1.00, CI: 0.80 to 1.25) was not associated with the incidence of MetS.</div></div><div><h3>Conclusion</h3><div>Possible SO, defined by low muscle mass, was not associated with subsequent new-onset MetS. This study highlights that the obesity component, rather than the muscle mass component, is the primary driver of MetS risk in middle-aged and older adults in China.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"49 ","pages":"Pages 69-76"},"PeriodicalIF":6.6,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming Barriers to Unlock the Therapeutic Potential of Saroglitazar for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease","authors":"Murali Krishna Moka ,&nbsp;Deepalaxmi Rathakrishnan ,&nbsp;Sriram D.K. ,&nbsp;Melvin George","doi":"10.1016/j.clnu.2025.03.024","DOIUrl":"10.1016/j.clnu.2025.03.024","url":null,"abstract":"","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"49 ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of cancer attributable to high body mass index: A systematic analysis of the Global Burden of Disease Study 2021","authors":"Gisella Figlioli ,&nbsp;Daniele Piovani ,&nbsp;Andreas G. Tsantes ,&nbsp;Nicola Pugliese ,&nbsp;Georgios K. Nikolopoulos ,&nbsp;Cesare Hassan ,&nbsp;Alessandro Repici ,&nbsp;Ana Lleo ,&nbsp;Alessio Aghemo ,&nbsp;Stefanos Bonovas","doi":"10.1016/j.clnu.2025.04.002","DOIUrl":"10.1016/j.clnu.2025.04.002","url":null,"abstract":"<div><h3>Background</h3><div>High body mass index (BMI) is a well-established cancer risk factor. Reliable, updated data are essential for guiding public health policies and designing effective interventions to reduce the cancer burden associated with high BMI.</div></div><div><h3>Methods</h3><div>Data from the Global Burden of Disease Study 2021 on cancer burden attributable to high BMI were analysed globally, stratified by sex, age, geographic region, cancer type, and socio-demographic index (SDI). Temporal trends in age-standardized rates from 1990 to 2021 were evaluated using estimated annual percentage changes.</div></div><div><h3>Results</h3><div>In 2021, cancer attributable to high BMI resulted in 356.74 thousand deaths (95% uncertainty interval: 146.12–581.01) and 8.89 million (3.75–14.38) Disability-Adjusted Life Years (DALYs), with females bearing the largest burden. From 1990 to 2021, age-standardized rates of high BMI-related cancer deaths increased by 0.35% annually, while DALYs rose by 0.42% annually. In 2021, the burden of cancer deaths and DALYs attributable to high BMI varied considerably across geographical regions. Low-middle SDI regions experienced the largest increases in death and DALY rates attributable to high BMI, while these rates declined in high SDI regions. Colon and rectum cancers accounted for the greatest number of deaths and DALYs, while pancreatic cancer showed the most rapid growth in attributable burden.</div></div><div><h3>Conclusions</h3><div>High BMI is a major contributor to the global cancer burden, with significant variation by sex, cancer type, region, and SDI level. Targeted public health strategies are urgently needed to mitigate the growing impact of overweight and obesity on cancer.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":"Pages 144-152"},"PeriodicalIF":6.6,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143807417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The physiological role of copper: Dietary sources, metabolic regulation, and safety concerns","authors":"Yuhan Fu,&nbsp;Lirui Hou,&nbsp;Kai Han,&nbsp;Chong Zhao,&nbsp;Hongbo Hu,&nbsp;Shutao Yin","doi":"10.1016/j.clnu.2025.03.023","DOIUrl":"10.1016/j.clnu.2025.03.023","url":null,"abstract":"<div><div>Copper plays an important physiological role in the body, with both deficiency and excess potentially impacting overall health. The body maintains a stringent copper metabolism mechanism to oversee absorption, utilization, storage, and elimination. Dietary consumption serves as the principal source of copper. The dietary factors may interfere with the absorption and metabolism of copper, leading to fluctuation of copper levels in the body. However, these dietary factors can also be strategically employed to facilitate the precise regulation of copper. This paper delved into the advancements in research concerning copper in food processing, including dietary sources of copper, the regulatory processes of copper metabolism and health implications of copper. The safety and its underlying mechanisms of excess copper were also highlighted. In particular, the paper examines the influence of dietary factors on the absorption and metabolism of copper, aiming to provide direction for accurate copper regulation and the creation of functional foods and pharmaceuticals.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":"Pages 161-179"},"PeriodicalIF":6.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating polyunsaturated fatty acids percentages and coronary artery disease incidence and mortality: Observational and Mendelian randomization analyses","authors":"Qiuxuan Liu,&nbsp;Yifan Kong,&nbsp;Haonan Kang,&nbsp;Yi Jiang,&nbsp;Xingjie Hao","doi":"10.1016/j.clnu.2025.03.020","DOIUrl":"10.1016/j.clnu.2025.03.020","url":null,"abstract":"<div><h3>Background</h3><div>The roles of polyunsaturated fatty acids (PUFAs) in preventing coronary artery disease (CAD) remain controversial. This study aimed to investigate the relationships between circulating PUFA percentages and CAD outcomes using observational and Mendelian randomization (MR) approaches.</div></div><div><h3>Methods</h3><div>We analyzed data from 203,373 UK Biobank participants without CAD at baseline. Four PUFA percentages (docosahexaenoic acid [DHA]%, omega-3%, linoleic acid [LA]%, and omega-6%) were examined in relation to incident CAD and CAD mortality. MR analyses included one-sample linear and nonlinear approaches, as well as two-sample univariable and multivariable methods. Observational and one-sample MR analyses were conducted overall and stratified by age and sex.</div></div><div><h3>Results</h3><div>During a median follow-up of 13.2 years, 16,098 incident CAD cases and 1243 CAD deaths occurred. Observationally, all PUFA percentages were inversely associated with both CAD outcomes. In one-sample MR, genetically predicted DHA% was strongly associated with decreased risk of CAD mortality (hazard ratio [HR] 0.31, 95 % confidence interval [CI] 0.15–0.62, <em>P</em> = 9.71 × 10⁻⁴), with a pronounced effect in individuals aged ≥58 years (HR 0.20, 95 % CI 0.09–0.43, <em>P</em> = 4.75 × 10⁻⁵). Genetically predicted omega-6% was associated with a decreased risk of incident CAD (HR 0.84, 95 % CI 0.76–0.92, <em>P</em> = 1.26 × 10⁻⁴), with a significant effect in females but not in males. Two-sample MR confirmed these findings, suggesting partial mediation through lipid pathways. Nonlinear MR analyses validated these linear associations without threshold effects.</div></div><div><h3>Conclusions</h3><div>Observational and genetically predicted high DHA% protects against CAD mortality, particularly in older adults. Omega-6% and incident CAD exhibited sex-specific inverse associations. These findings underscore the importance of considering age and sex in PUFA-based strategies for CAD prevention.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":"Pages 122-133"},"PeriodicalIF":6.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of high versus standard enteral protein provision on functional recovery following intensive care admission: A pre-planned Bayesian analysis of the PRECISe trial","authors":"Eline Schouteden ,&nbsp;Samuel Heuts ,&nbsp;Julia LM. Bels ,&nbsp;Steven Thiesen ,&nbsp;Rob JJ. van Gassel ,&nbsp;Zheng-Yii Lee ,&nbsp;Christian Stoppe ,&nbsp;Albertus Beishuizen ,&nbsp;Ashley De Bie Dekker ,&nbsp;Vincent Fraipont ,&nbsp;Stoffel Lamote ,&nbsp;Didier Ledoux ,&nbsp;Clarissa Scheeren ,&nbsp;Elisabeth De Waele ,&nbsp;Arthur van Zanten ,&nbsp;Sander MJ. van Kuijk ,&nbsp;Marcel CG. van de Poll ,&nbsp;Dieter Mesotten ,&nbsp;Andrea Gabrio ,&nbsp;the PRECISe study team","doi":"10.1016/j.clnu.2025.03.022","DOIUrl":"10.1016/j.clnu.2025.03.022","url":null,"abstract":"<div><h3>Background and aims</h3><div>High protein nutrition may improve outcomes after critical illness. We recently published the primary frequentist analysis of the PRECISe trial, showing that high (2.0 g/kg/day) compared with standard (1.3 g/kg/day) protein provision led to statistically significant worse health-related quality of life. The study, however, was not powered to draw definitive conclusions about clinical and other functional outcomes under a frequentist framework. We present a pre-planned and pre-specified Bayesian analysis to facilitate the clinical interpretation of these paramount endpoints.</div></div><div><h3>Methods</h3><div>The trial enrolled 935 patients and used the EQ-5D-5L health utility score as the primary endpoint. We performed Bayesian analyses of the primary and selected secondary endpoints, and relevant subgroups, under weakly informative priors. Sensitivity analyses were performed using skeptical and enthusiastic priors, and informed priors (when available) based on existing literature. Thresholds for clinically relevant differences were predefined.</div></div><div><h3>Results</h3><div>The posterior probability of benefit from high (2.0 g/kg/day) protein targets with respect to the EQ-5D-5L health utility score was 0 %. Concerning 60-day mortality, the posterior probability of any benefit from high protein provision was 8 %, with a posterior probability of clinically important harm (&gt;5 % absolute risk difference) of 47 %, which varied between 1 and 21 % across various sensitivity analyses under reference or literature-based priors.</div></div><div><h3>Conclusions</h3><div>This pre-planned Bayesian re-analysis of the PRECISe trial shows that high (2.0 g/kg/day) compared to standard (1.3 g/kg/day) protein provision in critically ill patients has a low probability to yield any benefit and results in a high probability of an increase of 60-day mortality.</div></div><div><h3>Registration number of clinical trial</h3><div>NCT04633421.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":"Pages 153-160"},"PeriodicalIF":6.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143807418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving the growth of infants with congenital heart disease using a consensus-based nutritional Pathway—A follow up study","authors":"Aneurin Young ,&nbsp;Catarina Fandinga ,&nbsp;Cai Davis ,&nbsp;Esther Andrews ,&nbsp;Mark J. Johnson ,&nbsp;Tara Bharucha ,&nbsp;R Mark Beattie ,&nbsp;Luise V. Marino","doi":"10.1016/j.clnu.2025.03.012","DOIUrl":"10.1016/j.clnu.2025.03.012","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Congenital Heart Disease (CHD) is the most common congenital abnormality, affecting 9 per 1000 live births. Advances in surgical techniques have significantly improved survival rates but growth failure is associated with increased risk of mortality post-cardiac surgery. Improving growth amongst infants with CHD whilst awaiting surgery is an important component to reducing morbidity as well as improving longer term metabolic outcomes. A consensus-based nutrition pathway was developed and implemented into a regional paediatric cardiology service in 2017. The aim of this study was to evaluate the impact of the pathway in a larger cohort of infants with CHD in two epochs: pre-nutrition pathway implementation (Jan 2013–Dec 2016) and post-nutrition pathway implementation (Jan 2017–June 2023).</div></div><div><h3>Methods</h3><div>Growth measures were extracted from electronic patient records and z-scores were calculated. SuperImposition by Translation And Rotation (SITAR) models were constructed to develop a single fitted curve of growth velocity for each of the two epochs.</div></div><div><h3>Results</h3><div>Infants with CHD in the post-implementation group achieved significantly better growth outcomes in the first 4-months of life. In addition, after adjustment for group differences, weight gain velocity was significantly higher in the post-implementation epoch (p = 0.01). There was no detectable change in the prevalence of overweight or obese children at older timepoints, suggesting that the intervention did not promote the development of obesity although further analysis will be required as the cohort gets older.</div></div><div><h3>Conclusion</h3><div>A nutrition pathway developed to support growth in infants with CHD before surgery was associated with better growth outcomes during the first year of life compared to an epoch when nutrition support was only given for malnourishment. Achieving normal growth patterns during the first year of life may help to reduce the risk of metabolic disease in later life, although further research will be required to elucidate this.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":"Pages 101-110"},"PeriodicalIF":6.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recognizing malnutrition in adults with critical illness: Guidance statements from the Global Leadership Initiative on Malnutrition.","authors":"R Fukushima, C W Compher, M I T D Correia, M C Gonzalez, L McKeever, K Nakamura, Z Y Lee, J J Patel, P Singer, C Stoppe, J C Ayala, R Barazzoni, M M Berger, T Cederholm, K Chittawatanarat, A Cotoia, J C Lopez-Delgado, C P Earthman, G Elke, W Hartl, M S Hasan, N Higashibeppu, G L Jensen, K J Lambell, C C H Lew, J I Mechanick, M Mourtzakis, G C C Nogales, T Oshima, S J Peterson, T W Rice, R Rosenfeld, P Sheean, F M Silva, P C Tah, M Uyar","doi":"10.1016/j.clnu.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.clnu.2025.03.011","url":null,"abstract":"<p><strong>Background: </strong>Patients with critical illness may present with disease-related malnutrition upon intensive care unit (ICU) admission. They are at risk of development and progression of malnutrition over the disease trajectory because of inflammation, dysregulated metabolism, and challenges with feeding.</p><p><strong>Methods: </strong>The Global Leadership Initiative on Malnutrition (GLIM) convened a panel of 36 clinical nutrition experts to develop consensus-based guidance statements addressing the diagnosis of malnutrition during critical illness, using a modified Delphi approach with a requirement of ≥75% agreement.</p><p><strong>Results: </strong>CONCLUSION: Research using consistent etiologic and phenotypic variables offers great potential to assess the efficacy of nutrition interventions for critically ill patients with malnutrition. Assessment of these variables at during and beyond the ICU stay will clarify the trajectory of malnutrition and enable exploration of impactful treatment modalities at each juncture. GLIM offers a diagnostic approach that can be used to identify malnutrition in critically ill patients.</p>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden Malnutrition in Obesity and Knee Osteoarthritis: Assessment, Overlap with Sarcopenic Obesity and Health Outcomes","authors":"Flavio T. Vieira ,&nbsp;Kristine Godziuk ,&nbsp;Rocco Barazzoni ,&nbsp;John A. Batsis ,&nbsp;Tommy Cederholm ,&nbsp;Lorenzo M. Donini ,&nbsp;M. Cristina Gonzalez ,&nbsp;Gordon L. Jensen ,&nbsp;Mary Forhan ,&nbsp;Carla M. Prado","doi":"10.1016/j.clnu.2025.03.019","DOIUrl":"10.1016/j.clnu.2025.03.019","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Malnutrition may be a hidden but relevant health condition in individuals with obesity and osteoarthritis. The Global Leadership Initiative on Malnutrition (GLIM) consensus includes muscle mass as one of the key phenotypic criteria, potentially enhancing its ability to detect malnutrition in individuals with obesity. We comprehensively profiled the nutritional status of individuals with obesity and advanced knee osteoarthritis and explored associations with health outcomes.</div></div><div><h3>Methods</h3><div>Data from the Prevention Of MusclE Loss in Osteoarthritis (POMELO) study was used, which included individuals with knee osteoarthritis and BMI≥35kg/m². Nutritional status was evaluated using the Global Leadership Initiative on Malnutrition (GLIM) and sarcopenic obesity (SO) criteria. Low muscle mass (dual-energy x-ray absorptiometry), inflammation (C-reactive protein), low muscle strength (handgrip/BMI), objective physical function (chair-stand test, 6-minute walk test), and self-reported measures (quality of life, arthritis symptoms, and self-efficacy) were evaluated. Linear regressions were performed between GLIM-malnutrition and health outcomes, adjusted by age.</div></div><div><h3>Results</h3><div>Forty-six individuals (73.9% female, age 64.2±6.7 years, BMI 42.4±4.7 kg/m2) were included. Regarding nutritional status, 26.1% were classified with malnutrition (i.e., defined by the combination of low muscle mass and elevated CRP concentration), 26.1% with SO, and 13% shared both conditions. Individuals with malnutrition presented with worse self-reported physical function (WOMAC function: 38.0±6.6 vs. 32.0±12.5, p=0.04) and lower arthritis self-efficacy (‘other symptoms’ component: 5.1±1.9 vs. 6.3±1.7, p=0.04) compared to those without malnutrition. A trend was identified for lower quality of life (visual analog scale 46.8±12.3 vs. 58.3±20.5, p=0.06) in those with malnutrition. Poor lipid control (R2=0.15, ß=0.76, 95% CI 0.08–1.44, p=0.030), body fat (R2=0.14, ß=5.56, 95% CI 1.01–10.11, p=0.018), and poor arthritis self-efficacy (R2=0.09, ß=-1.23, 95% CI -2.39–-0.06, p=0.040) were also associated with malnutrition.</div></div><div><h3>Conclusions</h3><div>Participants presented with high malnutrition rates (1 out of 4), and half of them also had SO. Malnutrition was associated with abnormal metabolic parameters, lower arthritis self-efficacy, and worse self-reported physical function. An early nutritional assessment and intervention may be imperative for individuals with osteoarthritis and obesity to mitigate health consequences.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The effects of 6 months dietary counseling on diet quality and cardiovascular risk profile in patients with cardiovascular disease: A randomized controlled trial” [Clin Nutr 45 (2025) 101–110]","authors":"Iris van Damme ,&nbsp;Eva R. van Veldhuisen ,&nbsp;Auke J.C.F. Verkaar ,&nbsp;Remy H.H. Bemelmans ,&nbsp;Marcel M.C. Hovens ,&nbsp;Frank L.J. Visseren ,&nbsp;Charlotte Koopal ,&nbsp;Renate M. Winkels ,&nbsp;Johanna M. Geleijnse","doi":"10.1016/j.clnu.2025.03.010","DOIUrl":"10.1016/j.clnu.2025.03.010","url":null,"abstract":"","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"48 ","pages":"Page 49"},"PeriodicalIF":6.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}